Education
About Us
Working with TipRanks
Follow Us
BioStem Technologies Inc (BSEM)
OTHER OTC:BSEM
Top Page
BioStem Technologies
(OTC:BSEM)
Select Model
Select Model
Rating:64Neutral
Price Target:
$8.00
▲(61.29% Upside)
BioStem Technologies' overall score reflects a strong financial performance and potential undervaluation, tempered by bearish technical indicators and mixed earnings call sentiment. The company's strategic initiatives and improved cash position are promising, but current market challenges and historical volatility pose risks.
BioStem Technologies (BSEM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$85.29M
Dividend YieldN/A
Average Volume (3M)93.59K
Price to Earnings (P/E)4.6
Beta (1Y)1.41
Revenue Growth133.77%
EPS Growth218.90%
CountryUS
Employees2
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.03
Shares Outstanding16,338,436
10 Day Avg. Volume84,611
30 Day Avg. Volume93,594
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap2.20
Enterprise Value/Revenue0.62
Enterprise Value/Gross Profit0.65
Enterprise Value/Ebitda5.96
Forecast
1Y Price Target
$8.00Price Target Upside61.29% Upside
Rating ConsensusHold
Number of Analyst Covering0
BioStem Technologies Business Overview & Revenue Model
Company DescriptionBioStem Technologies, Inc., a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases. The company is also engages in the repackaging and distribution of active pharmaceutical ingredients and other pharmaceutical compounding supplies; and develops and markets nutraceutical products under the Dr. Dave's Best and Nesvik Organics brands, as well as other non-proprietary products in the United States and internationally. The company sells products through e-commerce platforms. BioStem Technologies, Inc. was incorporated in 2006 and is based in Pompano Beach, Florida.
How the Company Makes MoneyBioStem Technologies generates revenue through multiple streams, primarily by selling its stem cell-based products to healthcare providers and clinics that utilize these innovations in their treatment protocols. The company may also engage in partnerships with hospitals and medical institutions to develop tailored regenerative medicine solutions, which can provide additional income through collaborative projects and research funding. Additionally, licensing agreements for its proprietary technologies or products can contribute to revenue, as well as potential royalties from successful applications of its therapies. Key factors influencing its earnings include the growing demand for regenerative medicine, successful clinical outcomes associated with its products, and the establishment of strong distribution networks.
BioStem Technologies Earnings Call Summary
Earnings Call Date:Aug 14, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:Nov 18, 2025
Earnings Call Sentiment Neutral
While BioStem continues to show operational and clinical progress with positive EBITDA and strategic growth plans, the significant revenue decline and reimbursement uncertainties present notable challenges. The sentiment is mixed, with strong financial metrics and future potential counterbalanced by current market and competitive pressures.Q2-2025 Updates
Positive Updates
Positive Adjusted EBITDA and Free Cash Flow
BioStem delivered its sixth consecutive quarter of positive adjusted EBITDA and positive free cash flow, maintaining industry-leading gross margins.
Strong Cash Position
The company ended the quarter with $30.8 million in cash, an increase from $20.6 million in Q1 2025.
Clinical Trial Milestone
Completed patient enrollment in the clinical trial evaluating BR-AC for treating diabetic foot ulcers, with top-line results expected in Q4 2025.
Operational Expansion Plans
Plans to expand and diversify the product portfolio through R&D and acquisitions, and strengthening commercial presence.
NASDAQ Uplisting Progress
Pursuing uplisting to NASDAQ as part of a long-term strategic plan, which includes increased visibility and expanded access to capital.
Negative Updates
Revenue Decline
Net revenue was $49.3 million, a 34% decrease from $74.5 million in Q2 2024, due to lower sales volume and increased competition.
Reimbursement Uncertainty
Products were omitted from the preliminary Medicare Part B ASP drug pricing file, impacting product selection and sales at the start of Q2.
Increased Competitive Pressure
The introduction of new competitive products with higher ASPs led to some customers choosing alternatives over BioStem's products.
Potential Impact of CMS Proposed Changes
The proposed Medicare reimbursement rule changes for skin substitutes could significantly impact the mobile wound care market.
Company Guidance
During the BioStem Technologies Second Quarter 2025 Earnings Call, several key metrics and guidance points were discussed. The company reported $49.3 million in net revenue, representing a 34% decrease from $74.5 million in Q2 2024, primarily due to reimbursement uncertainties and increased competition from higher-priced products. Despite these challenges, BioStem achieved its sixth consecutive quarter of positive adjusted EBITDA and free cash flow, ending the quarter with $30.8 million in cash, an increase from $20.6 million in Q1. Gross profit stood at $48.6 million, with an impressive gross margin of 98.6%, supported by the product mix benefits of VENDAJE AC. Operating expenses decreased to $48.5 million, down from $61.9 million in the prior year. The company reported a GAAP net loss of $564,000 or $0.03 per share, compared to a net income of $6.3 million or $0.39 per share in Q2 2024. These results are set against the backdrop of ongoing initiatives, including a clinical trial for the BR-AC product and efforts to address potential changes in Medicare reimbursement rules. BioStem also reiterated its commitment to a strategic NASDAQ uplisting, which is part of its long-term growth strategy.BioStem Technologies Financial Statement Overview
Summary
BioStem Technologies shows strong financial performance with significant revenue growth and profitability in the latest period. The balance sheet has improved with positive equity and manageable debt levels. Cash flow generation is robust, although historical volatility and leverage issues pose some caution.Income Statement
BioStem Technologies' TTM data shows a significant improvement with a strong gross profit margin of 95.4% and an impressive net profit margin of 11.0%. The revenue growth rate from 2023 to TTM is exceptionally high at 1709.0%, indicating robust top-line growth. EBIT and EBITDA margins of 10.3% and 10.4% respectively highlight the company's improved operational efficiency. However, prior years showed negative profitability, which suggests past volatility.82
Very Positive
Balance Sheet
The company's balance sheet reflects a significant recovery with positive stockholders' equity of $40.9 million and a manageable debt-to-equity ratio of 0.11. The equity ratio is 29.1%, indicating a moderate reliance on equity financing. However, previous years exhibited negative equity and high leverage, posing potential risks.67
Positive
Cash Flow
BioStem Technologies demonstrates strong cash flow management with operating cash flow exceeding net income, resulting in a robust operating cash flow to net income ratio of 0.74. The free cash flow to net income ratio is also favorable at 0.73. The free cash flow growth rate from 2023 to TTM is notable, reflecting improved cash generation capabilities. Historical data indicates previous challenges in cash flows.74
Positive
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 301.83M | 16.69M | 6.88M | 4.34M | 2.52M |
| Gross Profit | 287.86M | 15.42M | 5.99M | 2.87M | 1.25M |
| EBITDA | 31.49M | -7.55M | -6.52M | -602.00K | -1.59M |
| Net Income | 31.88M | -8.48M | -7.07M | -1.45M | -2.39M |
Balance Sheet | |||||
| Total Assets | 140.55M | 14.56M | 3.47M | 2.67M | 2.67M |
| Cash, Cash Equivalents and Short-Term Investments | 22.83M | 239.41K | 772.14K | 340.33K | 100.70K |
| Total Debt | 4.39M | 4.77M | 5.09M | 4.83M | 5.63M |
| Total Liabilities | 99.67M | 15.90M | 7.42M | 8.47M | 8.30M |
| Stockholders Equity | 40.88M | -1.34M | -4.08M | -5.96M | -5.80M |
Cash Flow | |||||
| Free Cash Flow | 24.05M | -3.60M | -2.11M | -152.29K | -585.25K |
| Operating Cash Flow | 24.48M | -3.50M | -1.64M | -109.44K | -581.57K |
| Investing Cash Flow | -1.68M | -210.33K | -469.48K | -7.85K | -3.69K |
| Financing Cash Flow | -206.78K | 3.18M | 573.12K | 357.42K | 541.52K |
BioStem Technologies Technical Analysis
Negative
4.96
Price Trends
8.71
Negative
10.89
Negative
12.08
Negative
Market Momentum
-1.01
Negative
29.50
Positive
17.15
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BSEM, the sentiment is Negative. The current price of 4.96 is below the 20-day moving average (MA) of 6.02, below the 50-day MA of 8.71, and below the 200-day MA of 12.08, indicating a bearish trend. The MACD of -1.01 indicates Negative momentum. The RSI at 29.50 is Positive, neither overbought nor oversold. The STOCH value of 17.15 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BSEM.
BioStem Technologies Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | $85.29M | 4.57 | 82.80% | ― | 133.77% | 218.90% | |
58 Neutral | 236.30M | -2.42 | -44.25% | ― | -70.38% | -683.06% | |
51 Neutral | 191.24M | -3.25 | -560.01% | ― | -75.77% | -31.24% | |
42 Neutral | 355.10M | -9.79 | 0.00% | ― | 0.00% | -31.78% | |
33 Underperform | 179.92M | 14.15 | 0.00% | ― | 0.00% | 0.00% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
BSEM
BioStem Technologies
4.96
-5.08
-50.60%
CBIO
Crescent Biopharma
12.94
-4.06
-23.88%
VYGR
Voyager Therapeutics
4.48
-1.84
-29.11%
DMAC
Diamedica Therapeutics
6.76
2.72
67.33%
BDTX
Black Diamond Therapeutics
3.35
-1.43
-29.92%
IPHA
Innate Pharma
1.94
-0.31
-13.78%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.